By: Megan Campbell, Puget Sound Business Journal
May 12, 2020 - Seattle biotech CEO Shawn Iadonato, who said last year that he wanted to take Kineta public, is keeping a close eye on the market. Iadonato said the biotech still aims to raise crossover funds this year with the goal of doing an initial public offering, but he has not specified a timeline for when that happens.
Financing Led by the Scott • Schlaepfer Family Foundation
Seattle, Wash. -- (May 5, 2020) Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, neuroscience and biodefense, announced today that they have successfully closed their most recent funding round totaling $5 million. This round was led by the Bellevue-based Scott • Schlaepfer Family Foundation.
The Scott • Schlaepfer Family Foundation honors individuals and organizations based on three guiding principles: freedom, service and civil liberty
Bellevue, Wash. -- (February 25, 2020) Phil Scott Schlaepfer and his family launched a new philanthropic foundation today, the Scott • Schlaepfer Family Foundation. The foundation is rooted in a deep commitment to honoring service and sacrifice and advancing opportunities for individuals and families who are committed to self-improvement.